RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Trung Huynh maintained a Buy rating on Merck & Company (MRK) with a $142 price target. This follows a recent Buy from Scotiabank, while Citi held a Hold rating. Additionally, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies.
In a report released today, Trung Huynh from RBC Capital maintained a Buy rating on Merck & Company, with a price target of $142.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Huynh covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer. According to TipRanks, Huynh has an average return of 22.2% and a 74.29% success rate on recommended stocks.
In addition to RBC Capital, Merck & Company also received a Buy from Scotiabank’s Louise Chen in a report issued yesterday. However, on the same day, Citi maintained a Hold rating on Merck & Company (NYSE: MRK).